Preface: Biomarkers in Critical Illness

Critical Care Clinics

Volumn 27, Issue 2, 2011, Pages

  Levy, Mitchell M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LACTIC ACID; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROCALCITONIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; HUMAN; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SEPSIS; TREATMENT DURATION; VITAL SIGN;

BIOLOGICAL MARKERS; CRITICAL ILLNESS; HUMANS;

EID: 79953001889     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2011.01.001     Document Type: Editorial

References (14)

1. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
2. Levy M.M., Macias W.L., Vincent J.L., et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005, 33:2194-2201.
3. Kumar A., Roberts D., Wood K., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in septic shock. Crit Care Med 2006, 34:1589-1596.
4. Marshall J.C., Vincent J.L., Fink M.P., et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003, 31:1560-1567.
5. Konstantinides S., Geibel A., Olschewski M., et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002, 106(10):1263-1268.
6. Meyer T., Binder L., Hruska N., et al. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000, 36(5):1632-1636.
7. Kostrubiec M., Pruszczyk P., Bochowicz A., et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005, 26(20):2166-2172.
8. Douketis J.D., Leeuwenkamp O., Grobara P., et al. The incidence and prognostic significance of elevated cardiac troponins in patients with submassive pulmonary embolism. J Thromb Haemost 2005, 3(3):508-513.
9. Pruszczyk P., Bochowicz A., Torbicki A., et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003, 123(6):1947-1952.
10. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
11. Gibot S., Cravoisy A., Kolopp-Sarda M.N., et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005, 33:792-796.
12. Reinhart K., Brunkhorst F.M. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007, 7:500-502.
13. The Biomarker Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
14. Wagner J.A., Williams S.A., Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007, 81:104-107.